ArticleBMC cancer2025

Agnostic phase II, multicenter, single-arm study with DURVAlumab plus carboplatin or cisplatin and etoposide as first-line treatment in extensive stage - Extrapulmonary Small Cell Carcinoma (EPSCC) patients - DURVASCC trial (GOIRC-01-2021).

Angela Damato et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.